# Disulfidptosis: A Metabolic Cell Death Mechanism with Therapeutic Potential in Cancer

**Authors:** Wubin Zhao, Qi Wang, Jun Zhang

PMC · DOI: 10.32604/or.2026.076406 · Oncology Research · 2026-03-23

## TL;DR

Disulfidptosis is a new type of cell death caused by disulfide bond buildup, which could be used to treat cancer by targeting specific metabolic pathways.

## Contribution

The paper introduces disulfidptosis as a novel regulated cell death mechanism with distinct metabolic features and therapeutic potential in cancer.

## Key findings

- Disulfidptosis is triggered by glucose deprivation in SLC7A11-high cells, leading to cytoskeletal collapse.
- It is distinct from other cell death types like apoptosis and ferroptosis, with unique metabolic dependencies.
- Disulfidptosis is active in cancers like hepatocellular carcinoma and lung adenocarcinoma.

## Abstract

Disulfidptosis is a newly identified form of regulated cell death (RCD) first described in 2023, representing a significant advance in understanding programmed cell death pathways. This unique cell death modality is characterized by abnormal intracellular accumulation of disulfide bonds and disruption of redox homeostasis, leading to cytoskeletal collapse without caspase activation. Disulfidptosis is primarily triggered by glucose deprivation in cells with high expression of solute carrier family 7 member 11 (SLC7A11). Under these conditions, insufficient NADPH supply prevents the effective reduction of accumulated cystine to cysteine, thereby inducing disulfide stress. Distinct from apoptosis, ferroptosis, cuproptosis, or pyroptosis, disulfidptosis exhibits unique metabolic dependencies and a hallmark feature of cytoskeletal disintegration. Current evidence indicates that this mechanism is operative in various tumor types, including hepatocellular carcinoma, colorectal cancer, and lung adenocarcinoma, suggesting its potential therapeutic relevance. Therapeutic strategies targeting disulfidptosis include modulation of metabolic pathways—such as the use of GLUT1 or G6PD inhibitors—to selectively induce this form of cell death in cancer cells. This review systematically summarizes current understanding, aiming to elucidate the unique mechanisms and therapeutic potential of disulfidptosis, and provides a foundational framework for future studies and the development of innovative strategies targeting tumor metabolic vulnerabilities.

## Linked entities

- **Genes:** SLC7A11 (solute carrier family 7 member 11) [NCBI Gene 23657]
- **Diseases:** hepatocellular carcinoma (MONDO:0007256), colorectal cancer (MONDO:0005575), lung adenocarcinoma (MONDO:0005061)

## Full-text entities

- **Genes:** SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513] {aka CSE, DYT17, DYT18, DYT9, EIG12, GLUT}, G6PD (glucose-6-phosphate dehydrogenase) [NCBI Gene 2539] {aka CNSHA1, G6PD1}, SLC7A11 (solute carrier family 7 member 11) [NCBI Gene 23657] {aka CCBR1, xCT}
- **Diseases:** lung adenocarcinoma (MESH:D000077192), Cancer (MESH:D009369), hepatocellular carcinoma (MESH:D006528), colorectal cancer (MESH:D015179)
- **Chemicals:** cystine (MESH:D003553), Disulfidptosis (-), cysteine (MESH:D003545), disulfide (MESH:D004220), NADPH (MESH:D009249), glucose (MESH:D005947)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13040280/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13040280/full.md

## References

115 references — full list in the complete paper: https://tomesphere.com/paper/PMC13040280/full.md

---
Source: https://tomesphere.com/paper/PMC13040280